Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Discovery could pave the way to smallpox Immunity

A team of scientists led by a Howard Hughes Medical Institute (HHMI) international research scholar has discovered the immune system mechanism that causes some mice to be more susceptible to mousepox than others.

9 Jun 2004

Experimental human monoclonal antibody shows striking benefit in patients with advanced melanoma

Early testing of an experimental human monoclonal antibody showed a striking benefit in patients with advanced melanoma, say researchers at The University of Texas M. D. Anderson Cancer Center, who presented their findings at the annual meeting of the American Society of Clinical Oncology.

7 Jun 2004

New way to identify cell growth

In a discovery that has relevance in a variety of fields, including human health, UC Riverside Assistant Professor of Biochemistry Frank Sauer and colleagues at UC Riverside, in Germany, and in Wisconsin, have found a new way to identify when a living cell begins to grow.

5 Jun 2004

Breakthrough in gene therapy

Despite a roller-coaster ride of ups and downs during the past 15 years, gene therapy has continued to attract many of the world's brightest scientists. They are tantalized by the enormous potential that replacing missing genes or disabling defective ones offers for curing diseases of many kinds.

3 Jun 2004

New way to identify when a living cell begins to grow

3 Jun 2004

Drug helps patients with metastatic colorectal cancer

A drug designed to cut off a tumor’s blood supply, when paired with a chemotherapy combination, resulted in significant improvement in survival in patients with metastatic colorectal cancer, the first time in decades that survival times have been extended in patients with this devastating form of advanced cancer.

3 Jun 2004

Drug to extend lives of colorectal cancer patients

A drug designed to cut off a tumor's blood supply, when paired with a chemotherapy combination, resulted in significant improvement in survival in patients with metastatic colorectal cancer, the first time in decades that survival times have been extended in patients with this devastating form of advanced cancer.

2 Jun 2004

Avastin study shows significant improvement in patients with metastatic colorectal cancer

Genentech, Inc. and Roche have announced that the New England Journal of Medicine published the first Phase III study of an anti-angiogenesis cancer therapy, showing that the addition of Avastin™ (bevacizumab) to the IFL chemotherapy regimen (5-FU/Leucovorin/ CPT-11) significantly extended survival in patients with first-line (previously untreated) metastatic colorectal cancer.

2 Jun 2004

Research may help to reduce infection and multiple organ failure after injury

While physicians are able to treat patients who suffer blood loss after major injuries, a large number of these patients go on to develop infections or multiple organ failure, in which the functioning of the body vital organ systems, such as the lungs, heart, kidneys of liver, go awry.

2 Jun 2004

New medical patent covering the generation of genetically enhanced therapeutic antigens

Morphotek, Inc. announced today the issuance of United States Patent 6,737,268 covering the generation of genetically enhanced therapeutic antigens.

2 Jun 2004

New therapy to send cancer-killing drugs directly to tumours

Disguising a molecule to get it past the body's immune system could greatly enhance the success of a groundbreaking new therapy, Cancer Research UK scientists report in the British Journal of Cancer this week.

2 Jun 2004

Double-punch approach to vaccine design more effective

A study revealing new information about how viral proteins move between cells and alert the immune system suggests that a double-punch approach to vaccine design would make them more effective.

1 Jun 2004

Novel molecular targeting technologies to deliver gene-silencing therapy

Researchers have combined novel molecular targeting technologies to deliver gene-silencing therapy specifically to tumor cells shielded by a normally impermeable obstacle, the blood brain barrier.

1 Jun 2004

Women exposed in adulthood to cytomegalovirus may be at greater risk of breast cancer

A study just published in the prestigious British Journal of Cancer by researchers at the University of Otago's Christchurch School of Medicine and Health Sciences and Dunedin School of Medicine, and the University of Melbourne, has found evidence of a link between a common virus and breast cancer in women under the age of 40 years.

31 May 2004

Blueprint for rational design of vaccines that induce desired T-cell responses

Investigators from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have conducted studies in mice to gain a new picture of how the immune system’s “killer” T cells are prompted to destroy infected cells. Their insights provide a blueprint for rational design of vaccines that induce desired T-cell responses.

27 May 2004

New target of a cancer-causing gene

Researchers from the Johns Hopkins Bloomberg School of Public Health and other institutions have identified a new target of a cancer-causing gene.

27 May 2004

Human Genome Sciences has begun dosing patients with chronic hep C drug

Human Genome Sciences, Inc. announced today that it has begun dosing patients in a Phase 2 clinical trial of Albuferon™ (albumin-interferon alpha) in patients with chronic hepatitis C who are naïve to interferon-alpha treatments.

27 May 2004

Research into flipping genes therapy by Leeds University

Graham Cook and Erica de Wynter of molecular medicine have secured £125,000 to investigate the unique way antibody genes are assembled and how they can be harnessed to fight disease.

25 May 2004

Possible new second-generation multiple sclerosis therapy

Scientists from Genencor International, Inc., have demonstrated in an in vivo model that a new variant of recombinant interferon-beta reduces the immunological response to the protein.

25 May 2004

Trial shows Daclizumab therapy improves multiple sclerosis outcome

A small clinical trial of patients with multiple sclerosis (MS) who did not respond to interferon alone found that adding the human antibody daclizumab improved patient outcome. Patients who received the combined therapy had a 78 percent reduction in new brain lesions and a 70 percent reduction in total lesions, along with other significant clinical improvements.

24 May 2004